自组装的烯酸-油酸纳米颗粒封装dcetaxel用于协同药物输送
Jeongro Lee1, Hy Dinh Nguyen1, Sura Saad Abdullah1
1Department of Pharmacy, College of Pharmacy, Ajou University, Suwon 16499, the Republic of Korea.
International journal of pharmaceutics
|October 6, 2025
概括
这项研究开发了新型纳米颗粒,将烯酸 (LEU) 和多塞 (DTX) 与油酸 (OA) 结合起来,用于增强前列腺癌治疗. 三重协同药物递送系统 (LOND) 显示了提高疗效和细胞吸收.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 药物输送系统 药物输送系统
背景情况:
- 前列腺癌的治疗往往需要组合疗法以提高疗效.
- 目前的药物输送系统在实现协同效应和有针对性的输送方面面临着挑战.
- 脂肪酸可以增强抗癌药物的输送和有效性.
研究的目的:
- 为了合成和表征两性烯酸乙酸 (LEU) - 油酸 (OA) 合纳米粒子 (LON).
- 开发dcetaxel (DTX) 封装LON (LOND) 用于前列腺癌的三重协同药物输送.
- 评估LOND系统的体外性能,释放动力学和细胞毒性.
主要方法:
- 合成LEU-OA合物 (LOC) 和自组装纳米粒子 (LON).
- 将DTX封装到LON中以形成LOND纳米粒子.
- 纳米粒子形态,大小,稳定性和药物释放动态的表征.
- 在体外细胞毒性测定使用PC3前列腺癌细胞和HFF-1纤维细胞.
- 对焦显微镜用于细胞吸收研究.
主要成果:
- 球形LON和LOND纳米粒子 (130.6-159.1nm) 已成功合成,并显示出良好的稳定性.
- 伦敦表现出优异的膜透性和高的淋巴吸收.
- 从伦敦观察到7天内从伦敦控制的LEU和DTX释放,受到酶活性的影响.
- 与单个药物相比,LOND对PC3细胞的细胞毒性明显更高,对正常细胞没有毒性.
- 在PC3和RAW 264.7细胞中证实了LOND的有效细胞吸收.
结论:
- 伦敦纳米粒子是前列腺癌治疗中三重协同药物输送的有希望的平台.
- 从LOND同时释放LEU,DTX和OA可以提高治疗效果.
- 这种新的纳米药物输送系统需要进一步研究前列腺癌治疗中的临床应用.
相关概念视频
Drug Delivery: Overview
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Drug Delivery Systems: Different Types
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


